Back to Search
ANDRES FORERO-TORRES, MD
MD
Hematology & Oncology Physician
NPI: 1265476352Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
25015(AL)
Research & Publications (8)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
PMID 19466965·Br J Haematol·2009
3-trial
Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.
PMID 18282361·Clin Lymphoma Myeloma·2007
6-review
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
PMID 16114986·Cancer Biother Radiopharm·2005
3-trial
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
PMID 19636010·J Clin Oncol·2009
3-trial
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
PMID 18182663·J Clin Oncol·2008
3-trial
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
PMID 17470451·Ann Oncol·2007
3-trial
Diffuse F-18 FDG uptake in skeletal muscles secondary to chills resulting from sepsis: a cause for underestimation of viable tumor.
PMID 15311141·Clin Nucl Med·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 619 19TH ST S
BIRMINGHAM, AL 35249 - Phone
- (205) 934-6600
Quick Facts
- NPI
- 1265476352
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 8
Are you this provider?
Claim Your Profile